These studies suggest that high Mcl-1 expression or Mcl-1 upregulation confer resistance to the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-263 in leukemias, lymphomas, melanomas and lung cancers [64–69]. The gene discussed is MCL1; the disease is melanoma.